Literature DB >> 24518921

[Genetic etiology of chronic inflammatory bowel disease].

S Schreiber1, P Rosenstiel, A Franke.   

Abstract

Crohn's disease and ulcerative colitis are the two main forms of inflammatory bowel disease. Inflammatory bowel diseases have a life time prevalence of up to 1 % in western industrialized countries. It is generally proposed that genetic susceptibility, which is much more widespread in the population, needs (unknown) factors in lifestyle in order to lead to disease manifestation. Systematic genome-wide association studies opened a new level of understanding of the risk architecture of inflammatory bowel diseases. This has led to the concept that barrier problems on the level of the intestinal epithelial cells may be a main driver in disease etiopathogenesis. Many of the newly discovered disease genes are not only relevant for inflammatory bowel disease but also for other disorders. This has initiated a large research interest in co-morbidities, which appear to be overlooked on the clinical side, too. Novel therapies should address the primary disease mechanisms and therefore provide causal interventions. Endpoints should include the avoidance of co-morbidities, which may be a limiting factor for patients with chronically active disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518921     DOI: 10.1007/s00108-013-3303-y

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

2.  Analyses of associations with asthma in four asthma population samples from Canada and Australia.

Authors:  Denise Daley; Mathieu Lemire; Loubna Akhabir; Moira Chan-Yeung; Jian Qing He; Treena McDonald; Andrew Sandford; Dorota Stefanowicz; Ben Tripp; David Zamar; Yohan Bosse; Vincent Ferretti; Alexandre Montpetit; Marie-Catherine Tessier; Allan Becker; Anita L Kozyrskyj; John Beilby; Pamela A McCaskie; Bill Musk; Nicole Warrington; Alan James; Catherine Laprise; Lyle J Palmer; Peter D Paré; Thomas J Hudson
Journal:  Hum Genet       Date:  2009-02-27       Impact factor: 4.132

3.  Correlation between genetic and geographic structure in Europe.

Authors:  Oscar Lao; Timothy T Lu; Michael Nothnagel; Olaf Junge; Sandra Freitag-Wolf; Amke Caliebe; Miroslava Balascakova; Jaume Bertranpetit; Laurence A Bindoff; David Comas; Gunilla Holmlund; Anastasia Kouvatsi; Milan Macek; Isabelle Mollet; Walther Parson; Jukka Palo; Rafal Ploski; Antti Sajantila; Adriano Tagliabracci; Ulrik Gether; Thomas Werge; Fernando Rivadeneira; Albert Hofman; André G Uitterlinden; Christian Gieger; Heinz-Erich Wichmann; Andreas Rüther; Stefan Schreiber; Christian Becker; Peter Nürnberg; Matthew R Nelson; Michael Krawczak; Manfred Kayser
Journal:  Curr Biol       Date:  2008-08-07       Impact factor: 10.834

4.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

5.  Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype.

Authors:  P Hindryckx; D Laukens; G Serry; L Van Praet; C Cuvelier; H Mielants; H Peeters; D Elewaut; M De Vos
Journal:  Ann Rheum Dis       Date:  2011-08-26       Impact factor: 19.103

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  Genomewide association study of leprosy.

Authors:  Fu-Ren Zhang; Wei Huang; Shu-Min Chen; Liang-Dan Sun; Hong Liu; Yi Li; Yong Cui; Xiao-Xiao Yan; Hai-Tao Yang; Rong-De Yang; Tong-Sheng Chu; Chi Zhang; Lin Zhang; Jian-Wen Han; Gong-Qi Yu; Cheng Quan; Yong-Xiang Yu; Zheng Zhang; Ben-Qing Shi; Lian-Hua Zhang; Hui Cheng; Chang-Yuan Wang; Yan Lin; Hou-Feng Zheng; Xi-An Fu; Xian-Bo Zuo; Qiang Wang; Heng Long; Yi-Ping Sun; Yi-Lin Cheng; Hong-Qing Tian; Fu-Sheng Zhou; Hua-Xu Liu; Wen-Sheng Lu; Su-Min He; Wen-Li Du; Min Shen; Qi-Yi Jin; Ying Wang; Hui-Qi Low; Tantoso Erwin; Ning-Han Yang; Jin-Yong Li; Xin Zhao; Yue-Lin Jiao; Li-Guo Mao; Gang Yin; Zhen-Xia Jiang; Xiao-Dong Wang; Jing-Ping Yu; Zong-Hou Hu; Cui-Hua Gong; Yu-Qiang Liu; Rui-Yu Liu; De-Min Wang; Dong Wei; Jin-Xian Liu; Wei-Kun Cao; Hong-Zhong Cao; Yong-Ping Li; Wei-Guo Yan; Shi-Yu Wei; Kui-Jun Wang; Martin L Hibberd; Sen Yang; Xue-Jun Zhang; Jian-Jun Liu
Journal:  N Engl J Med       Date:  2009-12-16       Impact factor: 91.245

9.  Structural localization of disease-associated sequence variations in the NACHT and LRR domains of PYPAF1 and NOD2.

Authors:  Mario Albrecht; Francisco S Domingues; Stefan Schreiber; Thomas Lengauer
Journal:  FEBS Lett       Date:  2003-11-20       Impact factor: 4.124

10.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  2 in total

1.  [Microbiome and nutrition. The way to a future therapy for chronic inflammatory bowel diseases?].

Authors:  S Schreiber; S Nikolaus; P Rosenstiel
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

Review 2.  [New biologics for treatment of chronic inflammatory bowel diseases].

Authors:  S Schreiber; O Bachmann
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.